Research analysts covering 22S.
Recent press releases and 8-K filings for 22S.
Nuwellis Reports Q3 2025 Financial Results and Operational Progress
22S
Earnings
CFO Change
New Projects/Investments
- Nuwellis reported total revenue of $2.2 million for the third quarter of 2025, representing a 6% decrease from Q3 2024. However, on a proforma basis, revenue grew approximately 7% year-over-year after excluding prior year Seastar Medical revenue and a decrease in international revenue.
- The company achieved net income attributable to common shareholders of $469,000, or $0.56 per share, for Q3 2025. Nuwellis ended the quarter with $3.1 million in cash and cash equivalents and remained debt-free.
- Operational highlights included year-over-year growth in circuit sales across all customer categories, higher console sales in heart failure and critical care, and the introduction of a new 24-hour Aquadex circuit and a dual-lumen extended length catheter.
- Nuwellis is transitioning manufacturing to KDI Precision Manufacturing and exited European operations to sharpen its U.S. focus. Additionally, Rob Scott concluded his 12-year tenure as Chief Financial Officer.
Nov 12, 2025, 2:00 PM
Quarterly earnings call transcripts for 22S.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more